Table 1.
Clinical characteristics of 500 patients with endometrial cancer from TCGA database
| POLE (N = 78) |
MSI (N = 123) |
Other (N = 299) |
Total (N = 500) |
|
|---|---|---|---|---|
| Stage | ||||
| Stage I | 48 (61.5%) | 89 (72.4%) | 172 (57.5%) | 309 (61.8%) |
| Stage II | 8 (10.3%) | 10 (8.1%) | 30 (10.0%) | 48 (9.6%) |
| Stage III | 19 (24.4%) | 20 (16.3%) | 77 (25.8%) | 116 (23.2%) |
| Stage IV | 3 (3.8%) | 4 (3.3%) | 20 (6.7%) | 27 (5.4%) |
| Grade | ||||
| G1 | 12 (15.4%) | 26 (21.1%) | 55 (18.4%) | 93 (18.6%) |
| G2 | 14 (17.9%) | 33 (26.8%) | 64 (21.4%) | 111 (22.2%) |
| G3 | 50 (64.1%) | 64 (52.0%) | 173 (57.9%) | 287 (57.4%) |
| High grade | 2 (2.6%) | 0 (0%) | 7 (2.3%) | 9 (1.8%) |
| Age | ||||
| < 60 | 45 (57.7%) | 50 (40.7%) | 72 (24.1%) | 167 (33.4%) |
| ≥ 60 | 31 (39.7%) | 73 (59.3%) | 227 (75.9%) | 331 (66.2%) |
| Missing | 2 (2.6%) | 0 (0%) | 0 (0%) | 2 (0.4%) |
| Radiation therapy | ||||
| No | 38 (48.7%) | 58 (47.2%) | 164 (54.8%) | 260 (52.0%) |
| Yes | 38 (48.7%) | 54 (43.9%) | 118 (39.5%) | 210 (42.0%) |
| Unknown | 2 (2.6%) | 11 (8.9%) | 17 (5.7%) | 30 (6.0%) |
| Diabetes | ||||
| No | 44 (56.4%) | 63 (51.2%) | 143 (47.8%) | 250 (50.0%) |
| Yes | 8 (10.3%) | 21 (17.1%) | 61 (20.4%) | 90 (18.0%) |
| Unknown | 26 (33.3%) | 39 (31.7%) | 95 (31.8%) | 160 (32.0%) |
| Hypertension | ||||
| No | 36 (46.2%) | 33 (26.8%) | 83 (27.8%) | 152 (30.4%) |
| Yes | 23 (29.5%) | 54 (43.9%) | 133 (44.5%) | 210 (42.0%) |
| Unknown | 19 (24.4%) | 36 (29.3%) | 83 (27.8%) | 138 (27.6%) |
| Menopause | ||||
| Pre | 10 (12.8%) | 5 (4.1%) | 17 (5.7%) | 32 (6.4%) |
| Peri | 6 (7.7%) | 4 (3.3%) | 7 (2.3%) | 17 (3.4%) |
| Post | 51 (65.4%) | 106 (86.2%) | 252 (84.3%) | 409 (81.8%) |
| Indeterminate | 2 (2.6%) | 5 (4.1%) | 8 (2.7%) | 15 (3.0%) |
| Unknown | 9 (11.5%) | 3 (2.4%) | 15 (5.0%) | 27 (5.4%) |
| BMI | ||||
| < 25 | 24 (30.8%) | 17 (13.8%) | 43 (14.4%) | 84 (16.8%) |
| ≥ 25 | 47 (60.3%) | 102 (82.9%) | 238 (79.6%) | 387 (77.4%) |
| Missing | 7 (9.0%) | 4 (3.3%) | 18 (6.0%) | 29 (5.8%) |